Bristol-Myers Squibb: Navigating Challenges & Innovation

Bristol-Myers Squibb, a biopharmaceutical giant, is experiencing a challenging period despite its innovative oncology drugs like Opdivo and Yervoy. The companys stock price has recently started to recover, but its still grappling with generic competition affecting its legacy portfolio, particularly Revlimid. Revenue from this portfolio dropped by 12% in Q3, totaling $5.4 billion. However, newer therapies like Reblozyl and Camzyos are showing promise, with an 18% revenue increase. The companys future success hinges on its innovative new drug pipeline, as it faces stiffer competition from rivals like Amgen.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.